Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study.

Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer

dexamethasone injection - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. (PubMed, Int J Clin Oncol) - Sep 4, 2026 - "An institutional dexamethasone-premedication strategy was associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab. Exploratory analyses found no significant differences in response or PFS; adequately powered studies with longer follow-up should determine whether dexamethasone premedication affects antitumor efficacy."
Journal • Oncology • Solid Tumor • Urothelial Cancer

http://www.ncbi.nlm.nih.gov/pubmed/42687064

; Haruhito Azuma; Hideki Enokida; Hideo Fukuhara; Junji Uchida; Junya Furukawa; Keiji Inoue; Keita Kobayashi; Keita Tamura; Kiyohide Fujimoto; Kohei Ogawa; Koichiro Wada; Koji Shiraishi; Makito Miyake; Mikio Sugimoto; Minoru Kato; Motoo Araki; Rikiya Taoka; Ryoei Minato; Ryu Shigehisa; Satoshi Katayama; Shuichi Tatarano; Takuya Tsujino; Teruo Inamoto; Yohei Abe; Yuki Oda; Yutaro Sasaki

Sep 4, 2026